Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Augmenting Parent Management Training for Child Temper Outbursts Using a Digital Tool

17 settembre 2026 aggiornato da: National Institute of Mental Health (NIMH)

Augmenting Parent Management Training With Naturalistic Skills for Child Temper Outbursts Using a Digital Tool

Background:

Pediatric disruptive behavior disorders (DBDs) are characterized by severe irritability, anger, and temper outbursts. The primary way to treat children with DBDs is parent management training (PMT). PMT teaches parents how to reward desired behaviors and not to reward undesired ones. Researchers want to find out if a smartphone app can help parents apply these skills more effectively.

Objective:

To test a smartphone app to enhance PMT.

Eligibility:

Children aged 8 to 13 years with DBDs. A parent or guardian is also needed.

Design:

Parents will have 12 weekly sessions of PMT. PMT teaches them how to manage their child s mood and behaviors. Parents will learn to actively ignore, praise, set limits, and handle temper outbursts. PMT can be either in person or via video. Sessions last 30 to 60 minutes. They will be video and audio recorded.

Parents will be divided into 2 groups. Only 1 group will download a smartphone app. The app helps parents practice PMT skills. It offers videos, a resource library, and alerts when a child may be at risk for various behaviors.

All parents will be prompted every day to answer questions about their child s mood and their own behavior. These will continue until 12 weeks after their last PMT session.

Children will also answer questions on their phone daily for 1 week at a time. They will do this on 3 different weeks, each about 2 months apart. They will also have check-ins by phone every 2 weeks for up to 6 months.

Parents will have follow-up calls 3, 6, and 12 months after they finish PMT.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Study Description:

This study is a feasibility study (N=60 parent-child dyads) of a digital tool (machine learning and a smartphone application) augmenting parent management training (PMT) to support the reduction of irritability and temper outbursts through changes in parenting behaviors (i.e., active ignoring) for pediatric disruptive behavior disorders (DBDs). We examine the feasibility of the study design (i.e., two-arm randomized controlled trial [RCT] of PMT + ecological momentary assessment [EMA] + digital tool vs. PMT + EMA + no digital tool) and examine patterns of change in irritability, outbursts, and parenting behaviors (i.e., active ignoring).

Objectives:

Primary Objective: Determine the feasibility of the design of a clinical trial (i.e., RCT with two parallel arms - PMT + EMA + digital tool compared to PMT + EMA + no digital tool).

Secondary Objective:

  • Determine whether outbursts and irritability decrease in PMT + EMA + digital tool and PMT + EMA + no digital tool. Determine whether severity of impairment decreases and general functioning improves in both groups.
  • Determine whether active ignoring increases in PMT + EMA + digital tool and PMT + EMA + no digital tool.

Tertiary Objective:

  • Examine whether attention deficit/hyperactivity disorder (ADHD), anxiety, and depression symptoms decrease in PMT + EMA + digital tool and PMT + EMA + no digital tool.
  • Monitor treatment acceptability and fidelity and therapeutic support.

Endpoints:

Primary Endpoint:

Dropout in each arm of the trial (PMT + EMA + digital tool vs. PMT + EMA + no digital tool).

Secondary Endpoint:

  • Changes in child outbursts and irritability measured using the Clinician-rated Affective Reactivity Index (CLARI); parent-/child-ARI; Brief Irritability Test (BITe); and parent/child EMA (collected 3x/day from baseline through 3 months post-treatment). Changes in severity of impairment and general functioning using the Children s Global Assessment Scale (CGAS), Clinical Global Impressions Scale-Severity (CGI-S), and Clinical Global Impress Scale-Improvement (CGI-I).
  • Changes in active ignoring measured using parent EMA (collected 3x/day from baseline through 3 months post-treatment).

Tertiary Endpoint:

  • Changes in symptoms of ADHD, anxiety, and depression. ADHD is measured using the ADHD Rating Scale (ADHD-RS) and Conners Parent Rating Scale (CPRS-R). Anxiety is measured using the Screen for Child Anxiety Related Disorders (SCARED) and Pediatric Anxiety Rating Scale (PARS). Depression is measured using the Mood and Feelings Questionnaire (MFQ) and Child Depression Rating Scale (CDRS).
  • We will monitor treatment acceptability using the Working Alliance Inventory (WAI) and treatment fidelity using an adherence scale previously developed by our group.

Tipo di studio

Osservativo

Iscrizione (Stimato)

200

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Maryland
      • Bethesda, Maryland, Stati Uniti, 20892
        • National Institutes of Health Clinical Center
        • Contatto:
          • NIH Clinical Center Office of Patient Recruitment (OPR)
          • Numero di telefono: TTY dial 711 800-411-1222
          • Email: ccopr@nih.gov

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino

Accetta volontari sani

No

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

This study is for children 8-13 years old with irritability as a primary clinical concern and no more than minimal response to current treatment. At least one parent/guardian must be willing to enroll and have the cognitive ability to consent, and the child must be able to understand and willing to sign a written assent document. The enrolled, consented parent must be willing to attend 12 parent management training sessions and use the study s digital tool. Both parent and child must be fluent in English. Exclusion criteria for children are active major depression or history of psychosis, bipolar I disorder, level 2 or 3 autism spectrum disorder, active severe substance use, active suicidal intent or plan, IQ below 70, or medical or neurological conditions that may interfere with study participation. Exclusion criteria for parents are IQ below 70, medical/mental health conditions that interfere with participation, or current substance or alcohol problems requiring separate treatment.

Descrizione

  • INCLUSION CRITERIA:

Inclusion Criteria for Youth:

To be eligible to participate, an individual must be enrolled in the 01-M-0254 protocol. All screening will occur under 01-M-0254 and all inclusion criteria for youth and parent or guardian will be determined under the 01-M-0254 protocol. To be eligible to participate, an individual must meet all the following criteria:

  • Enrollment into protocol 01-M-0254 for screening purposes
  • Age 8-13 years (8 years 0 months through 13 years 11 months)
  • Parent/guardian and/or child reports irritability as a primary clinical concern. Specifically, compared to his/her peers, the child exhibits markedly increased reactivity to negative emotional stimuli that is manifest verbally or behaviorally. For example, the child responds to frustration with extended temper tantrums (inappropriate for age and/or precipitating event), verbal rages, and/or aggression toward people or property. This criterion is assessed based on the clinical interview conducted with parent/guardian and child after consenting into protocol 01-M-0254 for screening.
  • On the basis of record review and interviews with child and parent or guardian, the research team agrees that the child s response to his/her current treatment is no more than minimal (i.e., CGI-S of 3 or more). This criterion is assessed based on the clinical interview conducted with parent/guardian and child after consenting into protocol 01-M-0254 for screening.
  • Patients must be fluent in (speaking, reading) English after consenting into protocol 01-M-0254 as determined through clinical judgement.

    --This study uses English-language manualized PMT. The PMT intervention materials, digital tool, therapist and rater training and supervision procedures, fidelity ratings, and outcome measures are currently available and validated only in English. Because psychotherapy relies on nuanced verbal exchange, use of translation or interpreters could alter treatment content, affect therapeutic alliance, compromise fidelity, and limit accurate clinical risk assessment. Enrolling non-English speakers can introduce a confound to our research objectives around feasibility, symptom and behavior change, and acceptability and fidelity. Restricting enrollment to English-speaking participants is therefore necessary to ensure participant safety and scientific validity in this trial. Critically, this eligibility criterion is based solely on the language requirements of the intervention and study procedures and is not intended to exclude participants on the basis of race or ethnicity or any other factors.

  • At least one parent or guardian of the minor subject must be willing to enroll in the protocol and have the cognitive ability to consent.
  • The minor subject must be able understand a written assent document as determined through clinical judgement, as well as be willing to sign a written assent document.

Inclusion Criteria for Parent or Guardian:

To be eligible to participate, an individual must be enrolled in the 01-M-0254 protocol. All screening will occur under 01-M-0254 and all inclusion criteria for youth and parent or guardian will be determined under the 01-M-0254 protocol. To be eligible to participate, an individual must meet all the following criteria:

  • Enrollment into 01-M-0254 for screening purposes
  • Parent or guardian of a child eligible for this protocol that can attend 12 PMT sessions and is willing to use the digital tool
  • Fluent in English after consenting into protocol 01-M-0254 as determined through clinical judgement
  • Ability of parent or guardian to understand the consent form and the willingness to sign a written informed consent document

EXCLUSION CRITERIA:

Exclusion Criteria for Youth:

All screening will occur under 01-M-0254 and all exclusion criteria for youth and parent or guardian will be determined under the 01-M-0254 protocol. Participants will be screened to exclude participants who would not be able to engage in psychotherapy. All individuals meeting any of the exclusion criteria at baseline will be excluded from participation.

  • Active major depressive disorder or history of psychosis, bipolar I disorder, Level 2 or 3 autism spectrum disorder, active severe substance use disorders (within the last month), have active suicidal intent or plan as detected on screening instruments
  • IQ < 70
  • Past or present medical or neurological condition, disease, disorder, genetic finding, or injury that, in the opinion of the Investigator, may significantly increase the potential risks of study participation, reduce or compromise a subject s ability to fully comply with all study requirements for the duration of the study or may compromise the integrity of the data.

Exclusion Criteria for Parent or Guardian:

All screening will occur under 01-M-0254 and all exclusion criteria for youth and parent or guardian will be determined under the 01-M-0254 protocol. Participants will be screened to exclude participants who would not be able to engage in psychotherapy. All individuals meeting any of the exclusion criteria at baseline will be excluded from participation.

  • IQ < 70 as assessed via a neuropsychological assessment or via assessment by trained clinical staff
  • Have any serious medical, mental health, or any condition that interferes with participation, such as active psychosis.
  • Current alcohol or substance use or dependence (excluding nicotine) within the past 3 months of sufficient magnitude to require independent, concurrent treatment intervention (e.g., antabuse or opiate treatment but not including self-help groups).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Children/adolescents with irritability
Parents/guardians of children/adolescents with irritability
Either parent management training alone or parent management training with a digital tool.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Dropout in each arm of the trial
Lasso di tempo: By parent management training session 12
Differential participant dropout in Group 1 (parent management training + digital tool) compared to Group 2 (parent management training + no digital tool) by parent management training session 12.
By parent management training session 12

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Clinician Affective Reactivity Index (CL-ARI)
Lasso di tempo: Pre-treatment, bi-weekly during treatment, mid-treatment, post-treatment, follow up (3-, 6-, and 12-months)
A 12-item clinician-administered measure of temper outbursts, irritable mood, and impairment over the past week, based on parent and child report.
Pre-treatment, bi-weekly during treatment, mid-treatment, post-treatment, follow up (3-, 6-, and 12-months)
Affective Reactivity Index (ARI)
Lasso di tempo: Pre-treatment, weekly during treatment, mid-treatment, post-treatment
A brief parent- and self-report measure of irritability with 6 core items (score range 0 12) and an additional impairment item not included in the total score.
Pre-treatment, weekly during treatment, mid-treatment, post-treatment
Brief Irritability Test (BITe)
Lasso di tempo: Pre-treatment, mid-treatment, post-treatment
A 5-item self-report measure assessing irritability over the past two weeks on a 6-point scale.
Pre-treatment, mid-treatment, post-treatment
Clinical Global Impressions Improvement (CGI-I)
Lasso di tempo: Pre-treatment, mid-treatment, post-treatment, follow up (3-, 6-, and 12-months)
A clinician-rated, diagnosis-independent measure of overall treatment response, assessing change from relative to a baseline on a 7-point scale (1 = very much improved to 7 = very much worse).
Pre-treatment, mid-treatment, post-treatment, follow up (3-, 6-, and 12-months)
Clinical Global Impressions Severity (CGI-S)
Lasso di tempo: Pre-treatment, bi-weekly during treatment, mid-treatment, post-treatment, follow up (3-, 6-, and 12-months)
A clinician-rated measure of the patient s current level of psychopathology on a 7-point Likert scale ranging from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients), providing a single global index of illness severity at the time of assessment.
Pre-treatment, bi-weekly during treatment, mid-treatment, post-treatment, follow up (3-, 6-, and 12-months)
The Children s Global Assessment Scale (CGAS)
Lasso di tempo: Pre-treatment, bi-weekly during treatment, mid-treatment, post-treatment, follow up (3-, 6-, and 12-months)
A clinician rated, diagnosis nonspecific measure of overall functioning in children and adolescents. It provides a single global rating of the child s psychological, social, and school functioning over a specified time period (usually the current level or past week), based on all available clinical information. Scored on a 100 point continuum divided into 10 point descriptive anchor ranges, with scores ranging from 1 (most impaired functioning) to 100 (superior functioning). Higher scores indicate better overall functioning, while lower scores reflect increasing levels of impairment.
Pre-treatment, bi-weekly during treatment, mid-treatment, post-treatment, follow up (3-, 6-, and 12-months)
Ecological momentary assessment (EMA) of child temper outbursts and irritability
Lasso di tempo: In both groups, parents/guardians complete EMA 3x/day from a baseline period through 12 weeks post-treatment (up to 30 weeks) and children complete EMA 3x/day for one week pre-, mid-, and post-treatment (3 weeks total)
EMA items are parent-report and child-report of child temper outbursts and irritability.
In both groups, parents/guardians complete EMA 3x/day from a baseline period through 12 weeks post-treatment (up to 30 weeks) and children complete EMA 3x/day for one week pre-, mid-, and post-treatment (3 weeks total)
Ecological momentary assessment (EMA) of parent active ignoring
Lasso di tempo: In both groups, parents/guardians complete EMA 3x/day from a baseline period through 12 weeks post-treatment (up to 30 weeks)
EMA items are parent-report of parent use of the active ignoring skill.
In both groups, parents/guardians complete EMA 3x/day from a baseline period through 12 weeks post-treatment (up to 30 weeks)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Melissa A Brotman, Ph.D., National Institute of Mental Health (NIMH)

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

23 settembre 2026

Completamento primario (Stimato)

31 dicembre 2036

Completamento dello studio (Stimato)

31 dicembre 2037

Date di iscrizione allo studio

Primo inviato

13 agosto 2026

Primo inviato che soddisfa i criteri di controllo qualità

13 agosto 2026

Primo Inserito (Effettivo)

14 agosto 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

17 settembre 2026

Ultimo verificato

8 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 10002714
  • 002714-M

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

In compliance with current NIH data-sharing policies, de-identified data from participants who have consented to data sharing will be made available in a public repository.

Periodo di condivisione IPD

De-identified data from participants who have consented to data sharing will be made available in a public repository at time of publication without an end date.

Criteri di accesso alla condivisione IPD

De-identified data from participants who have consented to data sharing will be made available in a public repository that can be accessed by anyone.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • ICF
  • CODICE_ANALITICO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .